Guggenheim Reiterates “Buy” Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a report released on Monday,Benzinga reports.

Other equities research analysts have also issued reports about the stock. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Barclays lifted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Trading Down 9.3 %

Tarsus Pharmaceuticals stock opened at $41.29 on Monday. The stock has a 50-day moving average price of $51.51 and a 200 day moving average price of $43.00. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -10.84 and a beta of 1.01. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts anticipate that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of TARS. Toronto Dominion Bank purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $105,714,000. Jennison Associates LLC raised its stake in shares of Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the period. Lord Abbett & CO. LLC lifted its position in shares of Tarsus Pharmaceuticals by 115.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after buying an additional 685,111 shares in the last quarter. Millennium Management LLC grew its stake in Tarsus Pharmaceuticals by 189.4% in the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock valued at $35,659,000 after acquiring an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after acquiring an additional 420,057 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.